Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M25-268 Phase 2a Platform Study of ABBV-142 in Idiopathic Pulmonary Fibrosis
jRCT2071260078Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing ABBV-142 with Placebo for ABBV-142 (2 arms). Primary endpoints: Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL) and Percentage of Participants with Adverse Events (AE). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ABBV-142
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2071260078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260078.